User profiles for John Varga
John VargaThe University of Michigan, Ann Arbor Verified email at umich.edu Cited by 49006 |
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative
…, RM Silver, RW Simms, J Varga… - Arthritis & …, 2013 - Wiley Online Library
Objective The 1980 American College of Rheumatology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …
ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus …
Pulmonary hypertension (PH) is a complex, multidisciplinary disorder. Recent advances
have led to increased recognition and new therapies. While some data exist to form …
have led to increased recognition and new therapies. While some data exist to form …
[HTML][HTML] Cyclophosphamide versus placebo in scleroderma lung disease
…, JR Seibold, DJ Riley, VM Hsu, J Varga… - … England Journal of …, 2006 - Mass Medical Soc
Background We conducted a double-blind, randomized, placebo-controlled trial to determine
the effects of oral cyclophosphamide on lung function and health-related symptoms in …
the effects of oral cyclophosphamide on lung function and health-related symptoms in …
[HTML][HTML] Systemic sclerosis: a prototypic multisystem fibrotic disorder
J Varga, D Abraham - The Journal of clinical investigation, 2007 - Am Soc Clin Investig
A unique feature of systemic sclerosis (SSc) that distinguishes it from other fibrotic disorders
is that autoimmunity and vasculopathy characteristically precede fibrosis. Moreover, fibrosis …
is that autoimmunity and vasculopathy characteristically precede fibrosis. Moreover, fibrosis …
[HTML][HTML] Recent developments in myofibroblast biology: paradigms for connective tissue remodeling
…, M Prunotto, A Desmoulière, J Varga… - The American journal of …, 2012 - Elsevier
The discovery of the myofibroblast has opened new perspectives for the comprehension of
the biological mechanisms involved in wound healing and fibrotic diseases. In recent years, …
the biological mechanisms involved in wound healing and fibrotic diseases. In recent years, …
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group …
…, J Golden, MK Connolly, J Varga… - The lancet Respiratory …, 2016 - thelancet.com
Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However, …
of scleroderma-related interstitial lung disease when compared with placebo. However, …
Systemic sclerosis
…, M Trojanowska, J Pope, CP Denton, J Varga - Nature reviews Disease …, 2015 - nature.com
Systemic sclerosis is a complex autoimmune disease characterized by a chronic and
frequently progressive course and by extensive patient-to-patient variability. Like other …
frequently progressive course and by extensive patient-to-patient variability. Like other …
Transforming growth factor β (TGFβ) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human …
J Varga, J Rosenbloom, SA Jimenez - Biochemical Journal, 1987 - portlandpress.com
It has been previously shown that transforming growth factor beta (TGF beta) is capable of
stimulating fibroblast collagen and fibronectin biosynthesis. The purpose of this study was to …
stimulating fibroblast collagen and fibronectin biosynthesis. The purpose of this study was to …
Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study
…, G Kujala, TA Medsger, VD Steen, J Varga… - Annals of internal …, 1994 - acpjournals.org
Objective: To evaluate the efficacy and safety of iloprost, a prostacyclin analog, administered
intravenously in patients with Raynaud phenomenon secondary to systemic sclerosis. …
intravenously in patients with Raynaud phenomenon secondary to systemic sclerosis. …
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative
…, S Sierakowski, RM Silver, RW Simms, J Varga… - 2013 - deepblue.lib.umich.edu
Objective. The 1980 American College of Rheuma-tology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …